Zealand Pharma A/S (OTCMKTS:ZLDPF) Stock Rating Upgraded by Barclays

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) was upgraded by equities researchers at Barclays to a "strong-buy" rating in a research note issued on Monday,Zacks.com reports.

Separately, BNP Paribas upgraded Zealand Pharma A/S to a "strong-buy" rating in a research report on Tuesday, July 1st. One equities research analyst has rated the stock with a buy rating and four have given a strong buy rating to the company's stock. Based on data from MarketBeat, Zealand Pharma A/S presently has an average rating of "Strong Buy".

Zealand Pharma A/S Price Performance

Shares of ZLDPF opened at $59.56 on Monday. The company has a debt-to-equity ratio of 0.03, a current ratio of 25.10 and a quick ratio of 25.07. The company's fifty day moving average price is $64.62 and its 200-day moving average price is $79.65. Zealand Pharma A/S has a 1-year low of $54.95 and a 1-year high of $141.74. The firm has a market capitalization of $4.23 billion, a PE ratio of -23.92 and a beta of 0.68.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.67) earnings per share for the quarter, beating the consensus estimate of ($0.77) by $0.10. The business had revenue of $1.14 million for the quarter, compared to the consensus estimate of $248.61 million. Zealand Pharma A/S had a negative return on equity of 13.40% and a negative net margin of 2,127.09%. On average, equities research analysts predict that Zealand Pharma A/S will post -2.19 EPS for the current year.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.